» Articles » PMID: 25713031

Biochemical Features and Antiviral Activity of a Monomeric Catalytic Antibody Light-chain 23D4 Against Influenza A Virus

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2015 Feb 26
PMID 25713031
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Catalytic antibodies have exhibited interesting functions against some infectious viruses such as HIV, rabies virus, and influenza virus in vitro as well as in vivo. In some cases, a catalytic antibody light chain takes on several structures from the standpoint of molecular size (monomer, dimer, etc.) and/or isoelectronic point. In this study, we prepared a monomeric 23D4 light chain by mutating the C-terminal Cys to Ala of the wild-type. The mutated 23D4 molecule took a simple monomeric form, which could hydrolyze synthetic 4-methyl-coumaryl-7-amide substrates and a plasmid DNA. Because the monomeric 23D4 light chain suppressed the infection of influenza virus A/Hiroshima/37/2001 in an in vitro assay, the corresponding experiments were conducted in vivo, after the virus strain (which was taken from a human patient) was successfully adapted into BALB/cN Sea mice. In the experiments, a mixture of the monomeric 23D4 and the virus was nasally administered 1) with preincubation and 2) without preincubation. As a result, the monomeric 23D4 clearly exhibited the ability to suppress the influenza virus infection in both cases, indicating a potential drug for preventing infection of the influenza A virus.

Citing Articles

Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies.

Hifumi E, Ito Y, Tsujita M, Taguchi H, Uda T Sci Rep. 2024; 14(1):12184.

PMID: 38806597 PMC: 11133420. DOI: 10.1038/s41598-024-63116-6.


Direct conversion of a general antibody to its catalytic antibody and corresponding applications -Importance and role of Pro95 in CDR-3.

Hifumi E, Taguchi H, Nonaka T, Uda T Proc Jpn Acad Ser B Phys Biol Sci. 2023; 99(6):155-172.

PMID: 37331814 PMC: 10319470. DOI: 10.2183/pjab.99.010.


Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.

Nonaka T, Taguchi H, Uda T, Hifumi E Int J Mol Sci. 2022; 23(22).

PMID: 36430828 PMC: 9697424. DOI: 10.3390/ijms232214351.


A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain.

Hifumi E, Nonaka T, Taguchi H, Uda T Sci Rep. 2022; 12(1):19185.

PMID: 36357546 PMC: 9649737. DOI: 10.1038/s41598-022-23689-6.


Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule.

Hifumi E, Taguchi H, Nonaka T, Harada T, Uda T RSC Chem Biol. 2021; 2(1):220-229.

PMID: 34458785 PMC: 8341958. DOI: 10.1039/d0cb00155d.